Citrullination of TNF-α by peptidylarginine deiminases reduces its capacity to stimulate the production of inflammatory chemokines

Cytokine

Volumn 61, Issue 1, 2013, Pages 161-167

  Moelants, Eva A V ^a   Mortier, Anneleen ^a   Grauwen, Karolien ^a   Ronsse, Isabelle ^a   Van Damme, Jo ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Citrullination; Cytokine; IL 1 ; Posttranslational modification; TNF

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN ARGININE DEIMINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CITRULLINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CELL LINE; CITRULLINE; FEMALE; FIBROBLASTS; HUMANS; HYDROLASES; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MICE; NEUTROPHIL ACTIVATION; NEUTROPHILS; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84869862967     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.09.011     Document Type: Article

References (40)

1. Dinarello C.A. Interleukin-1 Cytokine Growth Factor Rev 1997, 8:253-265.
2. Mortier A., Van Damme J., Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther 2008, 120:197-217.
3. Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P., et al. I, Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999, 274:3988-3993.
4. Mortier A., Gouwy M., Van Damme J., Proost P. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 2010, 317:642-654.
5. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008, 205:2085-2097.
6. Loos T., Mortier A., Gouwy M., Ronsse I., Put W., Lenaerts J.P., et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008, 112:2648-2656.
7. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
8. Tarcsa E., Marekov L.N., Mei G., Melino G., Lee S.C., Steinert P.M. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996, 271:30709-30716.
9. Gyorgy B., Toth E., Tarcsa E., Falus A., Buzas E.I. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38:1662-1677.
10. Yamada R., Yamamoto K. Mechanisms of disease: genetics of rheumatoid arthritis-ethnic differences in disease-associated genes. Nat Clin Practice Rheumatol 2007, 3:644-650.
11. Lundberg K., Nijenhuis S., Vossenaar E.R., Palmblad K., van Venrooij W.J., Klareskog L., et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005, 7:R458-R467.
12. Musse A.A., Boggs J.M., Harauz G. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci USA 2006, 103:4422-4427.
13. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
14. Larché M.J., Sacre S.M., Foxwell B.M. Pathogenic role of TNF[alpha] in rheumatoid arthritis. Drug Discov Today: Dis Mech 2005, 2:367-375.
15. Schiff M.H. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000, 59(Suppl 1):i103-i108.
16. Foulquier C., Sebbag M., Clavel C., Chapuy-Regaud S., Al Badine R., Mechin M.C., et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56:3541-3553.
17. Chang X., Yamada R., Suzuki A., Sawada T., Yoshino S., Tokuhiro S., et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:40-50.
18. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003, 34:395-402.
19. Holm A., Rise F., Sessler N., Sollid L.M., Undheim K., Fleckenstein B. Specific modification of peptide-bound citrulline residues. Anal Biochem 2006, 352:68-76.
20. Stensland M., Holm A., Kiehne A., Fleckenstein B. Targeted analysis of protein citrullination using chemical modification and tandem mass spectrometry. Rapid Commun Mass Spectrom 2009, 23:2754-2762.
21. Moelants E.A.V., Van Damme J., Proost P. Detection and quantification of citrullinated chemokines. PLoS ONE 2011, 6:e28976.
22. Van Damme J., Decock B., Conings R., Lenaerts J.P., Opdenakker G., Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. Eur J Immunol 1989, 19:1189-1194.
23. Wuyts A., Struyf S., Gijsbers K., Schutyser E., Put W., Conings R., et al. The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1beta and is down-regulated by interferon-gamma: comparison with interleukin-8/CXCL8. Lab Invest 2003, 83:23-34.
24. Proost P., Vynckier A.K., Mahieu F., Put W., Grillet B., Struyf S., et al. Microbial toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 2003, 33:3146-3153.
25. Proost P., Wuyts A., Conings R., Lenaerts J.P., Put W., Van Damme J. Purification and identification of natural chemokines. Methods 1996, 10:82-92.
26. Kim S., Ohoka N., Okuhira K., Sai K., Nishimaki-Mogami T., Naito M. Modulation of RIP1 ubiquitylation and distribution by MeBS to sensitize cancer cells to tumor necrosis factor alpha-induced apoptosis. Cancer Sci 2010, 101:2425-2429.
27. Lee S.Y., Cherla R.P., Tesh V.L. Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect Immun 2007, 75:1291-1302.
28. Thalayasingam N., Isaacs J.D. Anti-TNF therapy. Best Practice Res Clin Rheumatol 2011, 25:549-567.
29. 2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J Biol Chem 2010, 285:29750-29759.
30. Loos T., Opdenakker G., Van Damme J., Proost P. Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Haematologica 2009, 94:1346-1353.
31. Alivernini S., Fedele A.L., Cuoghi I., Tolusso B., Ferraccioli G. Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. Reumatismo 2008, 60:85-94.
32. Anzilotti C., Pratesi F., Tommasi C., Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 2010, 9:158-160.
33. Hueber W., Tomooka B.H., Zhao X., Kidd B.A., Drijfhout J.W., Fries J.F., et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007, 66:712-719.
34. Boyce B.F., Li P., Yao Z., Zhang Q., Badell I.R., Schwarz E.M., et al. TNF-alpha and pathologic bone resorption. Keio J Med 2005, 54:127-131.
35. Edwards C.J. Immunological therapies for rheumatoid arthritis. Brit Med Bull 2005, 73-74:71-82.
36. Mukai Y., Shibata H., Nakamura T., Yoshioka Y., Abe Y., Nomura T., et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 2009, 385:1221-1229.
37. Mukai Y., Nakamura T., Yoshioka Y., Tsunoda S., Kamada H., Nakagawa S., et al. Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009, 65:295-298.
38. Mukai Y., Nakamura T., Yoshikawa M., Yoshioka Y., Tsunoda S., Nakagawa S., et al. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010, 3:ra83.
39. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
40. Pimentel-Muinos F.X., Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999, 11:783-793.